ASP Isotopes appoints Ralph L. Hunter to board of directors and subsidiary role

ASP Isotopes Inc. (NASDAQ:ASPI), whose stock has surged over 270% in the past year according to InvestingPro data, announced Monday that its board of directors has increased its size to seven members and elected Ralph L. Hunter to fill the new vacancy, effective the same day. Despite recent volatility that saw an 11.6% decline last week, the company’s shares maintain an impressive 86% gain over the past six months. Hunter will serve as a Class II director, with his term set to expire at the company’s 2027 annual meeting of stockholders or until his earlier resignation or removal.

Hunter has also been appointed to the board of managers of Quantum Leap Energy LLC, a wholly owned subsidiary of ASP Isotopes .

According to a company statement based on a Securities and Exchange Commission filing, there is no arrangement or understanding between Hunter and any other person regarding his selection as director, and there are no family relationships between Hunter and other directors or executive officers. The company also stated it is not aware of any transactions involving Hunter that would require disclosure under SEC regulations.

Hunter, age 60, brings more than 35 years of experience in the nuclear power generation industry. Since June 2025, he has been chairman and CEO of RC Nuclear Consultants, LLC. His appointment comes at a crucial time for ASP Isotopes, which currently maintains strong liquidity with a current ratio of 14.7 and operates with a moderate debt level, as revealed in InvestingPro’s detailed financial analysis (unlock 12 more exclusive ProTips with a subscription). Previously, he served as president and CEO of Orion Nuclear Energy Corporation and held leadership roles at Constellation Energy Corporation’s international clean energy business. Hunter has also served as chair of the U.S. Civil Nuclear Trade Advisory Committee and was a board member at Rolls-Royce SMR Limited.

Hunter will receive compensation in accordance with ASP Isotopes’ non-employee director compensation policy. In connection with his board election, he received an award of 10,470 shares of restricted stock, which will vest in full on the one-year anniversary of the grant date, subject to continued service. He will be eligible for additional grants under the company’s compensation policy beginning at the 2025 annual meeting of stockholders.

Hunter has entered into the company’s standard form of indemnification agreement.

All information is based on a statement in the company’s filing with the Securities and Exchange Commission.

In other recent news, ASP Isotopes Inc. announced the pricing of a $60 million offering of common stock, with 7.5 million shares priced at $8.00 per share. This offering is expected to close soon, generating gross proceeds before expenses. Additionally, ASP Isotopes has formed a joint venture with Fermi America to develop advanced nuclear fuel production facilities in Texas. The collaboration aims to produce High Assay Low Enriched Uranium (HALEU) for small modular reactors. In a related development, ASP Isotopes signed a Memorandum of Understanding with Fermi America to explore the development of a HALEU enrichment facility in Carson County, Texas. This facility will utilize laser-based isotope separation technology to enhance domestic supply chains. Furthermore, ASP Isotopes invested $5 million in seed funding for IsoBio, a radiotherapeutic development company. Lastly, the company appointed Ralph L. Hunter, Jr., a veteran in the nuclear industry, to its board of directors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.